ReviewCanadian journal of gastroenterology = Journal canadien de gastroenterologie2006
Antibiotic therapy for Crohn's disease: a review.
Review in Canadian journal of gastroenterology = Journal canadien de gastroenterologie, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 27 citations in OpenAlex.
- NDP52 and its emerging role in pathogenesis.Cell death & disease · 2025Review
- Machine Learning Can Predict the Probability of Biologic Therapy in Patients with Inflammatory Bowel Disease.Journal of clinical medicine · 2022Article
- IL-1 and CD40/CD40L platelet complex: elements of induction of Crohn's disease and new therapeutic targets.Archives of pharmacal research · 2021Review
- Review
- A member of the gut mycobiota modulates host purine metabolism exacerbating colitis in mice.Science translational medicine · 2017Article
- Modulating Composition and Metabolic Activity of the Gut Microbiota in IBD Patients.International journal of molecular sciences · 2016Review
- [Diseases in gastroenterology].Der Internist · 2013Review
- The intestinal microbiota and chronic disorders of the gut.Nature reviews. Gastroenterology & hepatology · 2011Review
- Managing the risks of IBD therapy.Current gastroenterology reports · 2009Article
- Microbial host interactions in IBD: implications for pathogenesis and therapy.Current gastroenterology reports · 2007Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Increasing evidence suggests that gut bacteria play a pathogenic role in Crohn's disease (CD), providing a rationale for the use of antibiotics in the primary treatment of the disease. While there are data to suggest that antibiotics may be effective in treating active luminal, particularly colonic, and/or perianal CD, evidence for their use in these settings is hampered by the lack of well-designed, adequately powered, placebo-controlled trials. Furthermore, although nitroimidazole antibiotics have been shown to reduce postoperative recurrence following ileocolonic resection, their use is limited by side effects. There is a current need for rigorous multicentre studies looking into the role of antibiotics in treating perianal and luminal CD, as well as a need for the large-scale assessment of novel antibiotics, with low systemic absorption, which may improve patient tolerance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.